Unfortunately, we don't support Internet Explorer anymore as it has been replaced by Microsoft Edge. Please try using Edge or an alternative modern browser for the best experience.
Colin Hill is a leading voice in AI and precision medicine. He is the CEO and co-founder Aitia, a leading Digital Twin platform discovery and drug development company with a current focus on neurodegenerative diseases and oncology. He serves on the boards of Fulcrum Therapeutics (NASDAQ: FULC], a rare genetic disease company, Centrexion Therapeutics, a non-opioid pain therapeutics company, and the Critical Path Institute, which fosters collaborations between scientific and regulatory bodies.
He previously served on the boards of Biotelemetry Inc.(NASDAQ: BEAT), a mobile health company (acquired by Philips for $3B), CRO PPD Inc. (NASDAQ: PPD), (acquired by Thermo for $17B), and AesRx, a sickle cell disease biopharmaceutical company (acquired by Baxter in 2014).
In 2004, Colin was named to MIT Technology Review’s TR100 list of the top 100 innovators in the world under the age of 35. He has appeared in publications and television programs including The Wall Street Journal, CNBC Morning Call & SquawkBox, Nature, Boston Globe, Politico, Forbes, Wired, and The Economist. He graduated from Virginia Tech with a degree in physics and earned Master’s degrees in physics from McGill and Cornell.
